204 related articles for article (PubMed ID: 19925965)
1. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development.
Ma Z; Lienhardt C
Clin Chest Med; 2009 Dec; 30(4):755-68, ix. PubMed ID: 19925965
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
[TBL] [Abstract][Full Text] [Related]
4. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
Lienhardt C; Vernon A; Raviglione MC
Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
[TBL] [Abstract][Full Text] [Related]
5. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J
J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382
[TBL] [Abstract][Full Text] [Related]
6. Managing TB in the 21st century: existing and novel drug therapies.
Guy ES; Mallampalli A
Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
[TBL] [Abstract][Full Text] [Related]
7. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.
Andrews JR; Shah NS; Gandhi N; Moll T; Friedland G;
J Infect Dis; 2007 Dec; 196 Suppl 3():S482-90. PubMed ID: 18181698
[TBL] [Abstract][Full Text] [Related]
8. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities.
Lienhardt C; Davies G
Int J Tuberc Lung Dis; 2010 May; 14(5):528-37. PubMed ID: 20392344
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
10. Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children.
Schaaf HS; Moll AP; Dheda K
Clin Chest Med; 2009 Dec; 30(4):667-83, vii-viii. PubMed ID: 19925960
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for active tuberculosis.
Ginsberg AM
Semin Respir Crit Care Med; 2008 Oct; 29(5):552-9. PubMed ID: 18810688
[TBL] [Abstract][Full Text] [Related]
12. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
13. Extensively drug-resistant tuberculosis: current challenges and threats.
Jain A; Mondal R
FEMS Immunol Med Microbiol; 2008 Jul; 53(2):145-50. PubMed ID: 18479439
[TBL] [Abstract][Full Text] [Related]
14. Preclinical testing of new drugs for tuberculosis: current challenges.
Lenaerts AJ; Degroote MA; Orme IM
Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
[TBL] [Abstract][Full Text] [Related]
15. [Emergence extensive drug resistance tuberculosis (XDR)].
Vier H; Schaberg T; Gillissen A
Pneumologie; 2007 Sep; 61(9):606-9. PubMed ID: 17729211
[TBL] [Abstract][Full Text] [Related]
16. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
17. Treatment and prevention of tuberculosis in HIV-infected persons.
Cohn DL
Infect Dis Clin North Am; 1994 Jun; 8(2):399-412. PubMed ID: 8089467
[TBL] [Abstract][Full Text] [Related]
18. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
20. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist.
Mitrzyk BM
Pharmacotherapy; 2008 Oct; 28(10):1243-54. PubMed ID: 18823220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
